BMC Complementary Medicine and Therapies· 2026Q1
Targeting IL-10–mediated JAK–STAT signaling in cervical cancer: integrative network pharmacology, molecular docking, and experimental validation of Zerumbone
- 0citations
- Q1SCImago
- 2026year
Short summary
Zerumbone (ZER) significantly reduces IL-10 levels in cervical cancer cells, decreasing from 70.81 pg/mL at 1 µM to 6.32 pg/mL at 40 µM, thereby inhibiting cancer cell proliferation and promoting apoptosis via the JAK-STAT pathway.
AI-generated from the title and abstract; the full text is not read.
Key points
- Zerumbone (ZER) forms a stable complex with Interleukin-10 (IL-10) as predicted by molecular docking and simulations.
- ZER treatment significantly reduces IL-10 concentration in HeLa cervical cancer cells, from 70.81 pg/mL (1 µM ZER) to 6.32 pg/mL (40 µM ZER).
- ZER modulates downstream IL-10 targets, including Cyclin D1 and Bcl-xL, impacting cell proliferation and apoptosis.
- The IL-10 pathway, particularly JAK-STAT signaling, is identified as a key target for ZER's anticancer effects.
AI-generated from the title and abstract; the full text is not read.
Abstract
This study investigated the potential interaction between zerumbone (ZER) and interleukin-10 (IL-10) using molecular docking and molecular dynamics (MD) simulations. Computational analyses suggested a stable association of ZER with a functionally relevant region of IL-10. Gene Ontology (GO) and pathway enrichment analyses using STRING and KEGG identified IL-10’s primary involvement in the JAK-STAT signaling pathway, which regulates immune system homeostasis, inflammation, and cellular life. Zerumbone treatment was associated with reduced IL-10 levels and modulation of downstream signaling-associated markers, including Cyclin D1 and Bcl-xL. Cell-based assays have also corroborated dose-dependent modulation of IL-10 release in HeLa cells. There was a decrease in IL-10 concentration from 70.81 pg/mL at 1 µM to 6.32 pg/mL at 40 µM of ZER. The observed suppression of IL-10 and its target genes suggests that ZER modulates the apoptotic and proliferative signaling pathways, resulting in strong anticancer activity via the IL-10 pathway.
The authors' abstract, as published at the source. BMC Complementary Medicine and Therapies, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Pharmacology (Pharmacology, Toxicology and Pharmaceutics)
PharmacologyPharmacology, Toxicology and Pharmaceutics